Distinguished in Type 1 Diabetes (T1D)

Dr. Ronald L. Brazg

Endocrinology
723 Sw 10th St, Ste 250, 
Renton, WA 
Distinguished in Type 1 Diabetes (T1D)
723 Sw 10th St, Ste 250, 
Renton, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ronald Brazg is an Endocrinologist in Renton, Washington. Dr. Brazg is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Type 2 Diabetes (T2D), and Diabetic Ketoacidosis.

His clinical research consists of co-authoring 29 peer reviewed articles and participating in 31 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 18 articles and participated in 17 clinical trials in the study of Type 1 Diabetes (T1D).

Specialties
Endocrinology
Licenses
Internal Medicine in WA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

723 Sw 10th St, Ste 250, Renton, WA 98057

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

30 Clinical Trials

Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home
Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Device
Study Phase: Not Applicable
Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® (Insulin Aspart Injection)
Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® (Insulin Aspart Injection)
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2 - Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2 - Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
Enrollment Status: Completed
Publish Date: February 21, 2025
Intervention Type: Device
Study Phase: Not Applicable
Evaluation of the Impact of the FreeStyle Libre 2 Flash Glucose Monitoring System, Compared to the Current Standard of Care (SOC), on Weight Reduction in Subjects With Type 2 Diabetes.
Evaluation of the Impact of the FreeStyle Libre 2 Flash Glucose Monitoring System, Compared to the Current Standard of Care (SOC), on Weight Reduction in Subjects With Type 2 Diabetes.
Enrollment Status: Terminated
Publish Date: January 30, 2025
Intervention Type: Device
Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects Utilizing Lyumjev® Insulin Lispro-aabc
Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects Utilizing Lyumjev® Insulin Lispro-aabc
Enrollment Status: Completed
Publish Date: January 15, 2025
Intervention Type: Device
Study Phase: Not Applicable
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Device
Study Phase: Not Applicable
Use of the Guardian™ Connect System With Smart Connected Devices
Use of the Guardian™ Connect System With Smart Connected Devices
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Device
Study Phase: Not Applicable
Phase 1, Dose-Escalation Study of Nanoparticle Carrier-Formulated Self- Replicating Replicon RNA (repRNA) SARS-CoV-2 Vaccine (HDT-301) Targeting a Variant Spike Protein in Unvaccinated or Previously Vaccinated Healthy Adults
Phase 1, Dose-Escalation Study of Nanoparticle Carrier-Formulated Self- Replicating Replicon RNA (repRNA) SARS-CoV-2 Vaccine (HDT-301) Targeting a Variant Spike Protein in Unvaccinated or Previously Vaccinated Healthy Adults
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Biological
Study Phase: Phase 1
PROMISE Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days
PROMISE Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Device
Study Phase: Not Applicable
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Terminated
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults
Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Device, Drug
Study Phase: Not Applicable
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
Enrollment Status: Completed
Publish Date: June 02, 2023
Intervention Type: Device
Study Phase: Not Applicable
Feasibility Study With Personalized Closed Loop (PCL)
Feasibility Study With Personalized Closed Loop (PCL)
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Pilot Study of the Feasibility and Accuracy of the TrueVie Continuous Glucose Monitoring System - A Non-Significant Risk Study
A Pilot Study of the Feasibility and Accuracy of the TrueVie Continuous Glucose Monitoring System - A Non-Significant Risk Study
Enrollment Status: Completed
Publish Date: June 30, 2022
Intervention Type: Device, Other
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: October 01, 2021
Intervention Type: Device
Study Phase: Not Applicable
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
Enrollment Status: Completed
Publish Date: June 07, 2021
Intervention Type: Device
Study Phase: Not Applicable
User Experience and Daily Use Patterns With the Integrated Insulin Management (IIM) System
User Experience and Daily Use Patterns With the Integrated Insulin Management (IIM) System
Enrollment Status: Completed
Publish Date: January 07, 2021
Intervention Type: Drug, Device
Study Phase: Not Applicable
FreeStyle Libre Continuous Glucose Monitoring System Accuracy Study
FreeStyle Libre Continuous Glucose Monitoring System Accuracy Study
Enrollment Status: Completed
Publish Date: November 18, 2020
Intervention Type: Device
A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics
A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics
Enrollment Status: Withdrawn
Publish Date: September 29, 2020
Intervention Type: Device
Study Phase: Not Applicable
An Early Feasibility Study to Evaluate the Functionality and Safety of an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus During Meal Challenges
An Early Feasibility Study to Evaluate the Functionality and Safety of an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus During Meal Challenges
Enrollment Status: Completed
Publish Date: April 23, 2019
Intervention Type: Device, Drug
Study Phase: Not Applicable
An Early Feasibility Study to Evaluate the Functionality and Safety of an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus
An Early Feasibility Study to Evaluate the Functionality and Safety of an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: February 19, 2019
Intervention Type: Device, Drug
Study Phase: Not Applicable
Freestyle Libre Flash Glucose Monitoring System Accuracy Study
Freestyle Libre Flash Glucose Monitoring System Accuracy Study
Enrollment Status: Completed
Publish Date: November 29, 2018
Intervention Type: Device
An Early Feasibility Study to Evaluate the Functionality and Safety of an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus
An Early Feasibility Study to Evaluate the Functionality and Safety of an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: March 15, 2018
Intervention Type: Device, Drug
Study Phase: Phase 1
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
Enrollment Status: Completed
Publish Date: January 09, 2018
Intervention Type: Device
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
Enrollment Status: Completed
Publish Date: September 06, 2017
Intervention Type: Device
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
Enrollment Status: Completed
Publish Date: July 11, 2017
Intervention Type: Device
View 29 Less Clinical Trials

29 Total Publications

Safety and Functionality of a Novel Clinical Decision-Support Algorithm with Insulin Efsitora Alfa in Adults with Type 2 Diabetes: Early Feasibility Study.
Safety and Functionality of a Novel Clinical Decision-Support Algorithm with Insulin Efsitora Alfa in Adults with Type 2 Diabetes: Early Feasibility Study.
Journal: Diabetes technology & therapeutics
Published: May 12, 2025
Similar Doctors
Elite in Type 1 Diabetes (T1D)
Dr. Irl B. Hirsch
Endocrinology
Elite in Type 1 Diabetes (T1D)
Dr. Irl B. Hirsch
Endocrinology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (11.8 miles away)
206-288-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Irl Hirsch is an Endocrinologist in Seattle, Washington. Dr. Hirsch is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Type 2 Diabetes (T2D), and Diabetic Ketoacidosis.

Elite in Type 1 Diabetes (T1D)
Dr. Carla J. Greenbaum
Endocrinology
Elite in Type 1 Diabetes (T1D)
Dr. Carla J. Greenbaum
Endocrinology
University Of Washington Medical Ctr, 1959 Ne Pacific St, 
Seattle, WA 
 (12.9 miles away)
206-598-4882
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carla Greenbaum is an Endocrinologist in Seattle, Washington. Dr. Greenbaum is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). Her top areas of expertise are Type 1 Diabetes (T1D), Diabetic Ketoacidosis, Type 2 Diabetes (T2D), Congenital Hyperinsulinism, and Islet Cell Transplantation. Dr. Greenbaum is currently accepting new patients.

Elite in Type 1 Diabetes (T1D)
Dr. William Hagopian
Endocrinology
Elite in Type 1 Diabetes (T1D)
Dr. William Hagopian
Endocrinology
University Of Washington Medical Ctr, 1959 Ne Pacific St, 
Seattle, WA 
 (12.9 miles away)
206-598-4882
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Hagopian is an Endocrinologist in Seattle, Washington. Dr. Hagopian is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Type 1 Diabetes (T1D), Malabsorption, Diabetic Ketoacidosis, and Type 2 Diabetes (T2D).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brazg's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile